The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | The benefit of double autologous transplantation in multiple myeloma patient subgroups
Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, discusses which patients with multiple myeloma may benefit from a second autologous stem cell transplant, explaining that multiple studies have suggested double transplantation may benefit those patients in terms of overall survival (OS) and progression-free survival (PFS). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda; Advisory Board: Amgen, BMS, Celgene, Janssen, Karyopharm, Takeda.
